Stifel raised the firm’s price target on Veeva (VEEV) to $320 from $295 and keeps a Buy rating on the shares after “solid” Q2 results and FY26 EPS growth guidance being increased 18% year-over-year. The firm continues to view Veeva as a “stable mid-teens compounder with limited exposure to cyclical/trade risks,” the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva’s Clinical Platform selected by Amgen
- Veeva price target raised to $349 from $329 at Citi
- Veeva price target raised to $300 from $270 at Canaccord
- Veeva Systems: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Veeva price target raised to $355 from $325 at Piper Sandler